1. The gut--brain axis involves neural, immune and endocrine signalling pathways {#s0005}
================================================================================

The terms "gut--brain axis" and "brain--gut axis" denote the bidirectional communication between the gut and the brain ([Fig. 1](#f0005){ref-type="fig"}). Apart from the autonomic regulation of digestion by the central, parasympathetic, sympathetic and enteric nervous systems as well as by neuroendocrine factors (derived from the adrenal medulla and cortex), there is ongoing communication from the gut to the brain in health and disease. Normally, most information that is transmitted from the digestive system to the central nervous system does not reach the level of consciousness. However, visceral information is continuously fed into subcortical regions of the brain including the limbic system and the autonomic and neuroendocrine centres in the hypothalamus and brainstem. Under pathological conditions, the input from the gut can reach the cortex, giving rise to the sensation of nausea, discomfort or pain. This afferent part of the gut--brain--gut axis has recently been in the focus of investigation in order to understand why gastrointestinal disease is associated with pain and a number of psychiatric disturbances including anxiety, neuroticism and depression.

In a traditional view, the gut--brain axis uses 3 major information carriers for the communication between the gut and the brain ([Fig. 1](#f0005){ref-type="fig"}): neural messages carried by vagal and spinal afferent neurons, immune messages carried by cytokines, and endocrine messages carried by gut hormones. Each of these communication systems is abundantly present in the gastrointestinal tract which for this reason has been designated as a major neurological ([@b0460]), immune ([@b1035]) and endocrine ([@b0015; @b0725]) organ. The gastrointestinal immune system is important in defending the body against foreign antigens and pathogens that enter with the food and in maintaining homeostasis with the extensive microbial community living in the intestine. The gut microbiota and the gastrointestinal immune system interact with each other via the gastrointestinal mucosa, and this interaction has important functional implications within and outside the gastrointestinal tract.

It is increasingly emerging that the gut microbiota uses a fourth information pathway to signal to distant organs including the brain: apart from modulating the generation of cytokines in the intestinal immune system they also release signalling molecules such as lipopolysaccharide (LPS) and peptidoglycan components ([@b0175]) that can directly act on the central nervous system ([Fig. 1](#f0005){ref-type="fig"}). Thus, the physiological roles of the symbiotic gut microflora relate not only to the regulation of digestion, nutrition, mucosal function and intestinal immunity, but also to metabolic homeostasis, systemic immunity and brain function (emotion, mood, cognition). With more than 20 hormones produced, the gut is also a major endocrine organ ([@b0725]). Formed in specialised endocrine cells of the gastrointestinal mucosa, gut hormones are involved in the coordination of digestion, the signalling of hunger and satiety and the regulation of energy homeostasis, but also in the control of emotion and mood. Importantly, the 4 communication pathways between the gut and the brain do not operate in isolation but are closely interrelated with each other. For instance, cytokines and gut hormones can act on afferent neurons in the vagus nerve and in this way send messages to the brain. Understanding the operation of the gut--brain axis in health and disease is thus not only relevant to gastroenterology but also to neurology and psychiatry and is likely to reveal important targets for novel therapeutic strategies.

2. Neuropeptide Y, peptide YY and pancreatic polypeptide are expressed at distinct levels along the gut--brain axis {#s0010}
===================================================================================================================

The members of the neuropeptide Y (NPY) family of biologically active peptides, NPY, peptide YY (PYY) and pancreatic polypeptide (PP), are expressed by cell systems at distinct levels of the gut--brain axis. Consisting of 36 amino acids, NPY, PYY and PP share the PP fold (hairpin fold) tertiary structural motif. The N-terminus of NPY and PYY is readily truncated by dipeptidyl peptidase 4 (EC 3.4.14.5) and other enzymes (e.g., aminopeptidase-P, endopeptidase-24.11), yielding the fragments NPY~3--36~ and PYY~3--36~ ([@b0680; @b0665]). The functional implication of the NPY family of peptides in the gut--brain communication is corroborated by the occurrence of 5 NPY receptor types, termed Y1, Y2, Y4, Y5 and y6 (a human pseudogene), along the gut--brain signalling pathways. Coupled to pertussis toxin-sensitive G~i/o~ protein transduction mechanisms ([@b0820; @b0020]), the Y receptor subtypes display characteristic affinities for the different members of the peptide family and their fragments \[[@b0185; @b0020]). While NPY and PYY do not grossly differ in their affinities for the Y1, Y2 and Y5 receptors subtypes, it is particularly worth noting that PYY~3--36~ is a preferred agonist at Y2 receptors while PP binds preferentially to Y4 receptors ([@b0645; @b0185; @b0020]).

2.1. Pancreatic polypeptide {#s0015}
---------------------------

PYY and PP are almost exclusively expressed at the level of the digestive system, whereas NPY is found at all levels of the gut--brain and brain--gut axis ([Fig. 2](#f0010){ref-type="fig"}). PP, as its name implies, is postprandially secreted from the pancreas in which it is synthesised by endocrine F cells of the pancreatic islets ([@b0270]). In addition, PP is expressed in a sparse number of endocrine cells in the small and large intestine, these cells being distinct from PYY-positive cells ([@b0185]). Both the release of PP and the biological actions of PP on digestion and food intake, which are preferentially mediated by Y4 receptors, require signalling in the parasympathetic vagus nerve ([@b0900; @b0315]). Although Y4 receptors are expressed in the brain, and Y4 receptor knockout is associated with reduced anxiety- and depression-related behaviour ([@b0780; @b0950]), there is a lack of evidence that PP is produced in the brain, given that the immunoreactivity which was once believed to reflect PP turned out to be NPY ([@b0025; @b0220]).

2.2. Peptide YY {#s0020}
---------------

The major source of PYY in the gut is the endocrine L cell which occurs most abundantly in the lower gastrointestinal tract ([@b0270; @b0645; @b0185; @b0190; @b1000]). In addition, PYY-positive L cells contain glicentin, a proglucagon-derived peptide, glucagon-like peptide-1 and glucagon-like peptide-2 ([@b0270; @b0185]). Given that they likewise express gustducin, a taste-related G protein, as well as bitter and sweet taste receptors, the PYY-containing L cells are thought to be important chemosensors in the intestine ([@b0835]). Other, but minor sources of PYY in the digestive system are enteric neurons of the stomach ([@b0120]) and pancreatic endocrine cells ([@b0190]). Since PYY is postprandially released from intestinal L cells, the peptide is thought to be a satiety signal, which fits with its effect to reduce food intake ([@b0645]). Once released, PYY is in part cleaved to PYY~3--36~ which, unlike the parent peptide, is a preferential agonist at Y2 receptors ([@b0900; @b0190]). Evidence for the expression of PYY in the brain is comparatively sparse. [@b0720] used radioimmunoassay, immunocytochemistry and reverse transcription polymerase chain reaction to find expression of PYY in the human brain and pituitary gland. In the rodent brain, PYY-positive neurons have been localised to the hypothalamus, pons, medulla and spinal cord ([@b0270]).

2.3. Neuropeptide Y {#s0025}
-------------------

In contrast to PP and PYY, NPY is expressed at all levels of the gut--brain and brain--gut axis, the major systems expressing this peptide being enteric neurons, primary afferent neurons, several neuronal pathways throughout the brain and sympathetic neurons ([Fig. 2](#f0010){ref-type="fig"}). Within the gut, the major source of NPY is constituted by enteric neurons. NPY occurs in the two major enteric nerve plexuses and has been localised to distinct interneurons and descending inhibitory motoneurons of the myenteric plexus as well as to noncholinergic secretomotor neurons of the submucosal plexus ([@b0185]). In the inhibitory motor neurons, NPY is frequently colocalised with vasoactive intestinal polypeptide and nitric oxide synthase ([@b0865; @b0185]). In addition to enteric neurons, NPY is also expressed in postganglionic sympathetic neurons in which it is colocalised with noradrenaline and adenosine triphosphate ([@b0185; @b0435]). NPY is preferentially found in sympathetic neurons supplying the vascular system but is largely absent from sympathetic neurons innervating the gastrointestinal mucosa ([@b0590]).

A further but very minor source of NPY in the gut is provided by primary afferent neurons originating in the dorsal root ganglia ([@b0130]). Under physiological conditions the NPY content of these neurons is very low, but under conditions of nerve injury the expression of NPY can be markedly upregulated, particularly in medium- and large-sized sensory neurons ([@b0130]). Nerve injury and inflammation also has an impact on the presence of Y1 and Y2 receptors in primary afferent neurons, these receptors being primarily expressed by small, presumably nociceptive sensory neurons ([@b0130]). Within the spinal cord there is an abundant NPY-containing neuropil which is made of at least 3 different neuron populations: inhibitory interneurons also containing γ-aminobutyric acid (GABA), descending noradrenergic neurons originating in the locus coeruleus, and primary afferent nerve endings ([@b0130]). The abundance of NPY in the spinal cord is matched by an extensive distribution of Y1 receptors which in the rat and mouse have been localised to 7 distinct types of neurons within the dorsal horn of the spinal cord ([@b0130]). By contrast, Y2 receptors appear to occur exclusively on the central terminals of primary afferent neurons in the superficial laminae of the spinal cord ([@b0130]).

Within the brain, NPY is the most abundant neuropeptide, being expressed by a multitude of neuronal systems in regions spanning from the medullary brainstem to the cerebral cortex. In the context of the gut--brain axis it is particularly worth noting that NPY occurs in the nucleus of the solitary tract and ventrolateral medulla, periaqueductal grey and locus coeruleus, paraventricular nucleus of the thalamus, hypothalamus (arcuate nucleus, paraventricular nucleus and other regions), septum, hippocampus, amygdala, basal ganglia, nucleus accumbens and cerebral cortex ([@b1015; @b0520; @b0255]). Several important pathways utilising NPY as a neurotransmitter have been identified. These include noradrenergic neurons originating in the locus coeruleus of the brainstem and issuing both ascending and descending projections in the central nervous system, neurons expressing both NPY and agouti-related protein (AgRP) originating in the arcuate nucleus of the hypothalamus, and distinct pathways operating in the limbic system ([@b1015; @b0520; @b0255]). The major receptor subtypes which NPY acts on in the brain are the Y1 and Y2 receptors, the localization of which are discussed when the functional implications of NPY in the cerebral part of the gut--brain axis are considered. While Y1 and Y2 receptors are widely distributed in the central nervous system, the localization of Y4 and Y5 receptors is restricted to particular regions of the brain such as nucleus of the solitary tract, area postrema, nucleus ambiguus, hypothalamus, thalamus and amygdala ([@b0520; @b0645; @b0255; @b0950]).

3. NPY, PYY and PP play specific roles at distinct levels of the gut--brain axis {#s0030}
================================================================================

3.1. NPY, PYY and PP inhibit gastrointestinal motility and secretion and thereby alter the input to the brain {#s0035}
-------------------------------------------------------------------------------------------------------------

The gut hormones PYY and PP and the enteric neuropeptide NPY subserve many functions in the regulation of digestion, which have been reviewed elsewhere ([@b0335; @b0185; @b0190]). Thus, only a brief summary of their functional implications within the digestive system is given here. These implications cannot go unnoticed, however, because any change in gastrointestinal function will also issue messages sent to the brain ([Fig. 2](#f0010){ref-type="fig"}), either via a neural route or via the blood stream (gut hormones, cytokines). It is also obvious that the functional implications of NPY, PYY and PP depend critically on the expression of different Y receptor subtypes by the control and effector systems of digestion.

PP is released from the endocrine pancreas following a meal and acts preferentially via Y4 and Y5 receptors. It inhibits gastric emptying through an action that involves the vagus nerve; this effect may in part account for its ability to reduce appetite, an effect that also depends on intact vagal signalling ([@b0725; @b0315]). By targeting Y4 receptors on the intestinal epithelium, PP can also inhibit intestinal electrolyte and water secretion ([@b0980]). In addition, PP has an inhibitory action on intestinal motor activity and peristalsis ([@b0335]), an effect that in the guinea-pig small intestine is mediated by enteric neurons ([@b0440]).

PYY is released from intestinal L cells following a meal in proportion to energy intake, particularly by fat and protein ([@b0315]). The meal-evoked release of PYY occurs long before the nutrients have reached the lower gut where the PYY-expressing L cells are most abundant, which indicates that a neural mechanism including the vagus nerve is involved ([@b0330; @b0190]). Gastric acid secretion, cholecystokinin, bile acids and free fatty acids of a particular length (C12) also stimulate the release of PYY ([@b0645; @b0300]) as do short chain fatty acids (SCFAs), particularly butyrate, which are produced through fermentation of indigestible carbohydrates by the colonic microbiota ([@b0170]). Once released, part of PYY is enzymatically cleaved to PYY~3--36~, the major circulating form of PYY ([@b0680]). This transformation is paralleled by a shift in the Y receptor subtypes stimulated by the peptide: while the full length peptide activates Y1, Y2 and Y5 receptors, the effects of PYY~3--36~ are preferentially mediated by Y2 and, to some extent, Y5 receptors ([@b0680; @b0645; @b0190]).

PYY and PYY~3--36~ have profound effects on gastrointestinal motility and secretion. The inhibitory action of PYY and PYY~3--36~ on gut function is mediated by 3 major Y receptor subtypes: Y1 receptors on enterocytes, myenteric and submucosal neurons and endothelial cells, Y2 receptors on myenteric and submucosal neurons, extrinsic primary afferent nerve fibres, and Y4 receptors on enterocytes ([@b0185; @b0190; @b1010]). Plasma concentrations roughly equivalent to postprandial levels inhibit gastric acid secretion, gastric emptying, the cephalic phase of gallbladder contraction and mouth-to-caecum transit time ([@b0315]). The inhibition of gastric acid secretion involves Y1 and Y2 receptors and is mediated both by an action in the brainstem and stomach ([@b1050]), while the effect of PYY~3--36~ to increase gastric pressure via stimulation of Y2 receptors does not involve the vagus nerve ([@b0490]). PYY released by SCFAs (administered exogenously or produced by the intestinal microbiota) inhibits gastrointestinal motility and electrolyte and water secretion by neural and non-neural mechanisms ([@b0190]). In addition, PYY promotes mucosal cell differentiation ([@b0390]).

In physiological terms, PYY is thought to be a major mediator of ileal and colonic brakes which are set into operation when fat reaches the lower gut: the brakes slow gastric emptying and intestinal transit, which in conjunction with the antisecretory action of PYY facilitates nutrient absorption ([@b0800; @b0585; @b0740; @b1005; @b0190]). The effect of PYY and PYY~3--36~ to inhibit colonic transit in the mouse is mediated by Y2 receptors on the enteric nervous system ([@b1010; @b0975]). There is also growing evidence that PYY and NPY exert a tonic influence on gastrointestinal motor and secretory activity. While Y2 receptor antagonists *per se* do not alter gastric motor tone ([@b0490]), Y1 and Y2 receptor antagonism as well as PYY and NPY knockout modify colonic ion transport and motility ([@b0975]). The pertinent findings indicate that, both in the human and mouse colonic mucosa, PYY and NPY exert a tonic antisecretory effect mediated by epithelial Y1 and neural Y2 receptors. Colonic transit is tonically accelerated by Y1 receptor stimulation and tonically inhibited by Y2 receptor stimulation ([@b0975]).

Emerging evidence also suggests that PYY shares some of the incretin-like activity of glucagon-like peptide-1, another gut hormone derived from enteroendocrine L cells ([@b0200]). These cells use G protein-coupled receptors (GPRs) such as GPR119 to respond to luminal nutrients and to release glucagon-like peptide-1 as well as PYY. The effect of GPR119 agonism to improve glucose tolerance in association with enhanced glucose-induced circulating insulin concentrations is mediated by PYY ([@b0200]). This newly discovered role in glucose homeostasis makes PYY a potentially useful target for the treatment of diabetes and obesity.

The gastrointestinal Y receptor subtypes are prominently targeted by NPY which in the gut is expressed by inhibitory enteric motor pathways, secretomotor neurons and sympathetic neurons. NPY inhibits gastrointestinal motility as well as electrolyte and water secretion, and its inhibitory action on intestinal Cl^−^ secretion is seen in all regions of the intestine ([@b0860; @b0470; @b0465; @b0185]). Although Y2 receptors play a major role in the antisecretory/proabsorptive effect of NPY and PYY, Y1 receptors on secretomotor neurons and epithelial cells, and Y4 receptors on enterocytes are also likely to contribute ([@b0195; @b0980; @b0185]). The prominent location of Y receptor subtypes on enteric neurons is also responsible for the inhibitory effect of NPY on gastrointestinal motility ([@b0335]). Peristalsis in the guinea-pig small intestine is depressed by NPY through interruption of excitatory pathways in the enteric nervous system ([@b0455]).

3.2. NPY interacts with the immune system and promotes gastrointestinal inflammation {#s0040}
------------------------------------------------------------------------------------

There is ample evidence that NPY is among the neuropeptides which have a distinct impact on immune function, within and outside the gastrointestinal tract ([@b0090; @b1020; @b0225]). This is particularly true for NPY released from the sympathetic nerve fibres which in lymphoid tissues form close contacts with immune cells. Following release, NPY acts on Y receptors (notably of the Y1, Y2, Y4 and Y5 subtype) expressed by distinct classes of immune cells (e.g., dendritic cells, mononuclear cells, macrophages, granulocytes, T and B lymphocytes) to modify their activity ([@b1030; @b1025; @b0690; @b0225]). However, NPY acts not only as a neuroimmune transmitter but also as a paracrine or autocrine immune mediator, given that immune cells (e.g., B and T lymphocytes, macrophages) themselves are capable of producing and releasing NPY ([@b1020; @b1025]). In this way NPY can affect both innate and adaptive immunity, leading to either immune activation or suppression depending on its concentration, the Y receptors activated and cell types involved ([@b0090; @b1020; @b0225]). The effects of NPY include modulation of immune cell trafficking, T helper cell differentiation, cytokine secretion, natural killer cell activity, phagocytosis and production of reactive oxygen species ([@b0420; @b0090; @b1020; @b0225]).

In the gastrointestinal tract, NPY plays an important role in regulating inflammatory processes, given that NPY-containing nerve fibres are in close contact with immune cells such as IgA-producing lymphocytes in the mouse ileum lamina propria ([@b0895]). The proliferation of lymphocytes from the human colonic lamina propria is also stimulated by NPY ([@b0275]). The ability of NPY to promote colonic inflammation is supported by several lines of evidence. *Firstly*, NPY knockout mice are largely resistant to the induction of dextran sulfate sodium (DSS)-induced colitis ([@b0155; @b0760]). *Secondly*, the result of NPY deletion is reproduced by treatment with a NPY antisense oligodeoxynucleotide ([@b0790]) and by knockout or antagonism of Y1 receptors ([@b0395]), which demonstrates that the Y1 receptor plays a pivotal role in the proinflammatory effect of NPY. The antiinflammatory phenotype of Y1 receptor knockout mice results from a defect in antigen-presenting cell function, a reduction of TNF-α and IL-12 production by macrophages, and a decrease in the number of effector T cells ([@b1030]). *Thirdly*, experimentally induced colitis is associated with an increase in the colonic synthesis of NPY ([@b0155; @b0790; @b0065]), a reduction of colonic Y1 receptor expression and a loss of the antisecretory action of NPY in the colon ([@b0535]). In contrast, the colonic levels of PYY are decreased in rats with DSS-induced colitis ([@b0425]). These experimental data are in line with a decrease of colonic PYY levels in patients with inflammatory bowel disease ([@b0945; @b0285; @b0870]), while circulating levels of PYY and NPY are enhanced ([@b0010; @b0930]).

Given that NPY is an activator of antigen-presenting cell function and a negative regulator of T cell function ([@b1030; @b1020; @b1025; @b0225]), the impact of NPY on gut inflammation is complex and involves a variety of down-stream mechanisms. For instance, NPY enhances the expression of neuronal nitric oxide synthase which is a determinant of oxidative stress and subsequent inflammation ([@b0155]). It is conceivable that PYY and PP also influence the intestinal immune system, acting via the same Y receptors as NPY. The proinflammatory effect of NPY could in part be counter-regulated by the vasoconstrictor effect of the peptide, given that the sympathetic constriction of splanchnic resistance vessels is co-mediated by the sympathetic triad adenosine triphosphate (ATP), noradrenaline and NPY ([@b0435]). In addition, NPY is able to potentiate the constrictor effect of noradrenaline and ATP. Both the vasoconstrictor response to NPY and its action to augment noradrenaline- and ATP-induced mesenteric vasoconstriction are mediated by postjunctional Y1 receptors ([@b0435]).

3.3. The impact of the gut microbiota on the gut--brain axis may involve NPY and PYY {#s0045}
------------------------------------------------------------------------------------

Endocrine cells in the gut mucosa are in direct contact with the intestinal microbiota, and there is emerging evidence that an interaction between these systems has an impact on the satietogenic and metabolic effects of gut hormones including PYY ([@b0145; @b0215]). In order to comprehend the implications of this relationship a brief survey of the emerging roles of the gut microbiota in the gut--brain axis is in place. The intestinal microflora is relevant to nutrition, digestion, metabolic homeostasis, local and systemic immune function, and neurobiological homeostasis ([@b0675; @b0140; @b0365; @b0250; @b0095]). It has even been shown that, within a critical window of time, the presence of commensal gut microbiota is required for normal brain development and synaptogenesis ([@b0400]). A change in the composition of the gut microbiota is an important factor leading to gastrointestinal immune activation ([@b0885]). Likewise, dysbiosis of the intestinal microflora ([@b0555; @b0940; @b0495]) and upregulation of mucosal Toll-like receptors ([@b0655]) have been implicated in the aetiology of irritable bowel syndrome (IBS). Analysis of the faecal microbiota reveals subgroups of IBS patients who either have a normal composition of gut microbiota or show substantial microbiota-wide changes characterised by an increased *Firmicutes*:*Bacteroidetes* ratio ([@b0495]). A number of clinical variables, including rectal pain threshold and depression, are associated with distinct microbial signatures, which may have a bearing on the pathophysiology and diagnosis of this functional gastrointestinal disorder ([@b0495]).

The contention that intestinal dysbiosis, as has been found to occur in patients with IBS ([@b0555; @b0940; @b0495]), contributes to the psychiatric comorbidity seen in these patients is backed by three lines of experimental investigation: experimental changes in the intestinal microbiota composition, neurobiological and behavioural phenotyping of germ-free mice, and analysis of the systemic effects of probiotics. Antibiotic-induced dysbiosis of the intestinal microflora increases the expression of brain-derived neurotrophic factor in the hippocampus and enhances exploratory behaviour ([@b0100]). Memory is impaired in germ-free mice, and exposure to stress combined with *Citrobacter rodentium* infection causes prolonged memory dysfunction ([@b0345]). Long-term treatment of mice with the probiotic *Lactobacillus rhamnosus* has a significant impact on brain neurochemistry, reduces anxiety- and depression-related behaviour and improves stress coping ([@b0125]). These behavioural effects are mediated by the vagus nerve and are associated with region-dependent alterations in the cerebral GABA receptor expression ([@b0125]).

The impact of intestinal dysbiosis on brain function takes place independently of inflammation and does not depend on the autonomic nervous system ([@b0100]). In addressing the question as to how gastrointestinal microbiota signal to the brain, several possibilities come to mind: constituents of the microbiota themselves ([@b0175]), sensory neurons, circulating cytokines, and gut hormones. Administration of *Escherichia coli* LPS into the rat jejunum causes vagal afferent input to the nucleus of the solitary tract ([@b0340]) as does intraperitoneal injection of interleukin-1β or tumour necrosis factor-α ([@b0445]). It is worth noting that the anxiolytic and antidepressant effects of probiotics are blocked by vagotomy ([@b0105; @b0125]).

There is some evidence that the NPY--PYY system has an impact on the composition and function of the gut microbiota and its relevance to the gut--brain axis. For instance, NPY has been found to exhibit a direct antimicrobial effect against various gut bacteria including *E. coli*, *Enterococcus faecalis*, and *Lactobacillus acidophilus* ([@b0280]). A relationship between the gut microbiota and the enteroendocrine PYY system can be envisaged if the role of gut microbiota in the fermentation of nondigestible carbohydrates is considered. While the human gut has a limited repertoire of glycoside hydrolases, the gut microbiota synthesises a large arsenal of these enzymes which process complex dietary carbohydrates to SCFAs, principally acetate, propionate, and butyrate ([@b0855]). Fermentation of prebiotic fibre also promotes satiety and lowers hunger and energy intake, an effect that is associated with enhanced release of glucagon-like peptide-1 and PYY from the gut ([@b0145; @b0140; @b0215]). Since PYY is a satiety factor, it is conceivable that it contributes to the prebiotic-induced reduction of food intake. The effect of PYY on energy homeostasis, along with that of PP and NPY, is dealt with in a separate section of this review.

The mechanisms of the interaction between microbiota, SCFAs and PYY-releasing L cells are still little understood. On the one hand, prebiotic supplementation may lead to a long-term change in gut microbiota composition. On the other hand, SCFAs which have many effects on gut mucosal physiology ([@b0375; @b0610]) may directly interact with the PYY-producing cells since Gpr41, a G protein-coupled receptor for SCFAs, is expressed by a subset of enteroendocrine cells in the gut epithelium ([@b0855]). Colonisation of the mouse colon with a fermentative human microbial community increases the plasma level of PYY, an effect that is blunted by knockout of Gpr41. Gpr41 deficiency is associated with a reduced expression of PYY, an increase in intestinal transit rate and an attenuation of energy harvest ([@b0855]). Microbiota-fermented SCFAs acting via Gpr41 on PYY-expressing L cells could thus be an important link in microbial--host communication.

3.4. The NPY system protects against distinct behavioural disturbances caused by peripheral immune challenge {#s0050}
------------------------------------------------------------------------------------------------------------

Infection and inflammation are increasingly recognised to contribute to the pathogenesis of mood disorders including major depression ([@b0815; @b0205; @b0615]). Peripheral induction of cytokines by infection or cancer often induces a sequence of behavioural alterations comprising sickness followed by depression, these effects being abrogated by cytokine antagonists or cytokine synthesis blockers ([@b1065; @b0030; @b0245; @b0815; @b0205; @b0810]). Emerging clinical evidence suggests that activation of the intestinal immune system by constituents of the intestinal microbiota can give rise to a similar syndrome of behavioural alterations ([@b0620]). Bacterial cell wall components such as LPS may penetrate the intestinal mucosal barrier once it has become leaky ([@b0615]) as a result of stress, low-grade intestinal inflammation or a dysbalance between the intestinal microbiota and the intestinal immune system. As a consequence, translocation of bacterial cell wall constituents or intestinal bacteria themselves across the intestinal mucosa has been proposed to be a pathogenetic factor in psychiatric diseases such as depression and chronic fatigue syndrome ([@b0620]). In support of this hypothesis, the serum concentrations of immunoglobulin A and M against lipopolysaccharide of gram-negative enterobacteria are increased in patients with major depression ([@b0615]).

Experimentally, the impact of peripheral immune challenge on brain function and behaviour can be modelled by systemic administration of LPS or Bacille Calmette-Guérin (BCG). These interventions induce the formation of cytokines and evoke a behavioural syndrome that follows a distinct time course ([@b1065; @b0205; @b0710]). Initially, a response termed "sickness behaviour" is observed, including anorexia, reduction of locomotion and a decrease in social interaction. Once the sickness behaviour in terms of anorexia and sedation is over, behavioural symptoms indicative of depression such as anhedonia and passive stress coping may persist for several weeks ([@b0325; @b0710; @b0765]). The signalling pathways whereby peripheral immune challenge alters brain mechanisms involve proinflammatory cytokines such interleukin-6, tumour necrosis factor-α and interferon-γ, which reach the brain via the bloodstream but also excite vagal afferent neurons and lead to the expression of cytokines by cerebral microglial cells and astrocytes ([@b0030; @b0245; @b0815; @b0205]).

The impact of peripheral immune challenge on brain function and behaviour involves several brain nuclei ([@b0325]) that express NPY and various Y receptors. NPY is involved in the regulation of emotional-affective behaviour ([@b0405; @b0820; @b0705]), and there is indirect evidence that NPY-expressing neurons in the arcuate and paraventricular nuclei of the hypothalamus counteract the behavioural responses to immune stress and infection ([@b0635; @b0915; @b0660]). This implication has been borne out in knockout experiments in which the cerebral NPY-Y receptor system has been found to protect against distinct behavioural disturbances in response to peripheral immune challenge. For instance, deletion of NPY as well as NPY plus PYY aggravates the BCG-induced loss of body weight and markedly delays recovery from this weight loss ([@b1085]). This finding attests to an important physiological role of NPY and PYY in maintaining energy homeostasis in the face of infection and immune stimulation ([@b1085]).

Analogous observations have been made when the acute sickness and delayed depression-like responses to LPS are analysed in Y2 and Y4 knockout mice. Thus, Y2 receptor knockout mice are particularly susceptible to the acute action of LPS to attenuate locomotion and suppress social interaction ([@b0750]). In contrast, the LPS-induced rise of temperature and circulating corticosterone is suppressed by Y2 receptor knockout ([@b0750]). The short-term effect of LPS to enhance anxiety is enhanced in Y2 and Y4 receptor knockout mice ([@b0750; @b0755]). In Y4 receptor knockout mice, the anxiogenic response to LPS persists at least for 4 weeks post-treatment by which time it has waned in WT mice ([@b0755]). Depression-related behaviour is enhanced 1 day post-LPS in control and Y2 receptor knockout mice, but not in Y4 receptor knockout mice. Four weeks post-treatment the depressogenic effect of LPS has waned in wild-type mice, but is maintained in Y2 receptor knockout mice and first observed in Y4 receptor knockout mice ([@b0755]). Thus, knockout of Y2 and/or Y4 receptors unmasks the ability of immune challenge with LPS to cause a delayed and prolonged increase in anxiety- and/or depression-like behaviour. These findings suggest that NPY acting via Y2 and Y4 receptors prevents the development of long-term anxiety- and depression-like behaviour caused by immune challenge ([@b0755]).

3.5. NPY inhibits nociceptive transmission in the spinal cord and brainstem {#s0055}
---------------------------------------------------------------------------

Abdominal pain arises from various conditions such as ulceration, perforation, muscle spasms, intestinal obstruction and inflammation (e.g., oesophagitis, gastritis, colitis). As in other tissues, inflammation has a major impact on the nociceptive system, and the pain associated with post-infectious IBS is likewise associated with low-grade inflammation and immune activation in the colonic mucosa. The propensity of the gut towards inflammation is related to its task to defend the body against antigens and pathogens, and to the huge microbiota community that inhabits the colon and is balanced by the local immune system. Apart from its adverse impact on bowel function, inflammation causes hyperalgesia and pain, given that inflammatory mediators sensitise nociceptive pathways ([@b0450; @b0475; @b0540]). Hypersensitivity to pain stimuli can develop in all components of the sensory innervation of the gastrointestinal tract, which is unique since 2 major populations of sensory neurons with input to the central nervous system are present: spinal afferent neurons originating from the dorsal root ganglia, and vagal afferent neurons originating primarily from the nodose ganglion. Neurophysiologically distinct populations of these afferent neurons supply the mesentery, serosa, muscularis and mucosa of the alimentary canal and differ in their sensory modalities ([@b0475; @b0540]).

Spinal afferent neurons, which contain low amounts of NPY, terminate in the spinal cord where interneurons and descending noradrenergic neurons express appreciable amounts of NPY ([@b0130; @b0905]). An abundant occurrence of Y1 and Y2 receptors in the spinal cord enables NPY to play an important role in the processing of incoming nociceptive information. Germ-line knockout of Y1 receptors or conditional knockdown of NPY is associated with thermal, chemical and mechanical hyperalgesia ([@b0730; @b0890; @b0775; @b0910]). Inflammation-independent pain evoked by intraperitoneal injection of MgSO~4~ and inflammation-dependent visceral pain evoked by intraperitoneal injection of acetic acid is likewise exacerbated by Y1 receptor deletion ([@b0730]). Peripheral inflammation leads to an upregulation of Y1 receptors in spinal afferent neurons and in the dorsal horn of the spinal cord ([@b0500]). However, these studies have primarily focused on somatic pain, and it awaits to be explored whether the antinociceptive role of NPY in the spinal cord also holds true for visceral pain. Two major mechanisms whereby NPY controls pain transmission in the spinal cord have been envisaged: inhibition of transmitter release from the terminals of primary afferent neurons, mediated primarily by Y2 receptors, and inhibition of postsynaptic neurons in the dorsal horn, mediated primarily by Y1 receptors ([@b0130; @b0905]).

Apart from spinal sensory neurons, vagal afferent neurons have also been established to play a role in visceral nociception, particularly in visceral chemonociception. Thus, vagal afferents signal intragastric acid challenge to the nucleus tractus solitarii (NTS) as visualised by expression of c-Fos, a marker of neuronal activation, and evoke behavioural reactions indicative of pain ([@b0875; @b0560]). Y2 and Y4 receptors are the Y receptor subtypes prevailing in the rat NTS ([@b0385; @b0565; @b0235; @b0795]), and gene deletion experiments have revealed that endogenous NPY acting via Y~2~ and Y~4~ receptors controls the chemonociceptive input from the stomach to the brainstem ([@b1045]). Specifically, the intragastric acid-evoked expression of c-Fos in the NTS is enhanced in Y2 and Y4 receptor knockout mice. Further analysis has shown that NPY acting via Y2 and Y4 receptors depresses the gastric input to the NTS by a central site of action ([@b1045]).

NPY may be both a transmitter and modulator of the communication between vagal afferents and their projection neurons in the NTS, since this neuropeptide ([@b0570]) as well as Y1, Y2 and Y4 receptors ([@b0290; @b0385; @b0565; @b1075; @b0235; @b0795; @b0550]) are expressed by certain vagal afferents and NTS neurons. While the Y2 receptor-mediated effects of NPY arise most likely from a presynaptic site of action on vagal afferents ([@b0290; @b1075]), the site of Y4 receptors in the control of afferent input to the brainstem remains to be analysed. The role of NPY in the gut--brain axis at the level of the brainstem is not limited to the control of chemonociceptive input but also extends to the reflex control of visceral functions. Thus, stimulation of Y receptors in the brainstem influences gastric motility, acid secretion and mucosal integrity ([@b0165; @b1055; @b1050]).

3.6. NPY may protect from the impact of stress on the gut--brain axis {#s0060}
---------------------------------------------------------------------

Physical stress such as infection, immune challenge, inflammation and pain as well as psychosocial stress have a marked impact on brain function and behaviour. Chronic abdominal pain, which is a common symptom of inflammatory bowel disease and functional gastrointestinal disorders ([@b0540]), is frequently accompanied by anxiety and mood disorders ([@b0625; @b0360; @b0935]), and psychological stress and depression go often hand in hand with an aggravation of intestinal inflammation ([@b0695; @b0350]). Psychosocial stress is also known to trigger or exacerbate visceral pain, and IBS is frequently associated with stress hypersensitivity and impaired stress coping ([@b0575; @b0595; @b0735; @b0925]). Neuroanatomical and functional brain imaging studies indicate that noxious signals from the body are processed in brain areas that are closely interrelated with the neuronal circuitry relevant to anxiety and mood ([@b0630]). Experimental studies confirm that gastrointestinal inflammation alters emotional-affective behaviour in a gender-dependent manner ([@b0785; @b0355; @b0760]). Thus, experimental gastritis is associated with an increase of anxiety in female mice ([@b0785]), whereas experimental colitis enhances anxiety-related behaviour in male and depression-like behaviour in female mice ([@b0760]).

Since NPY plays a role in pain, mood and stress coping, it may also be relevant to the impact of stress on the gut--brain axis. This argument takes account of a large body of experimental and clinical evidence that NPY is an important regulator of emotional processing. NPY as well as Y1, Y2 and Y5 receptors are widely expressed in cerebral areas critical to the regulation of anxiety, mood, cognition and stress resilience ([@b0520; @b0405; @b0820; @b0295; @b0705]). The expression of NPY in the human brain is related to polymorphisms in the NPY gene, and a low NPY expression genotype is associated with negative emotional processing, diminished stress resilience, a risk for major depression, and a reduced antidepressant treatment response ([@b1080; @b0230; @b0685]). Exposure of individuals with a low NPY expression genotype to negative stimuli causes an exaggerated activation of the amygdala, medial prefrontal cortex and anterior cingulate cortex ([@b1080; @b0230; @b0685]). The concentration of NPY in the cerebrospinal fluid and plasma is reduced in patients with post-traumatic stress disorder, while trauma-exposed individuals who do not develop or have recovered from post-traumatic stress disorder have enhanced plasma levels of NPY ([@b0715; @b1060; @b0840]). It is argued, therefore, that the cerebrospinal and plasma concentration of NPY is a biological correlate of resilience to or recovery from the adverse effects of stress ([@b1060]).

Animal experiments confirm that NPY is involved in the emotional processing of stress. The amygdala, which is a key brain region coordinating behavioural stress responses ([@b0640]), contains high levels of NPY and Y1, Y2, Y4 and Y5 receptors ([@b0795; @b0520; @b0550; @b1040; @b0950]). Intracerebroventricular and intraamygdalar administration as well as amygdalar overexpression of NPY have an anxiolytic effect which is primarily mediated by Y1 receptors, although other receptors (e.g., Y5) may also contribute ([@b0410; @b0515; @b0920; @b0805; @b0305]). The action of NPY to attenuate anxiety- and depression-related behaviour and improve stress coping is corroborated by the anxiogenic and depressive phenotype of NPY and Y1 receptor knockout mice ([@b0060; @b0505; @b0510; @b0760]). In contrast, genetic deletion or pharmacological antagonism of Y2 and Y4 receptors attenuates anxiety- and depression-like behaviour ([@b0825; @b0985; @b0045; @b0780; @b0950; @b0955]), which indicates that NPY signalling via Y2 and Y4 receptors has a negative impact on emotional-affective behaviour. The opposing effects of Y2 and Y1 receptor activation are due to their differential location at cerebral synapses: NPY-mediated transmission via excitatory postsynaptic Y1 receptors is counter-regulated by presynaptic Y2 receptor activation which inhibits the release of NPY and other transmitters ([@b0405; @b0160; @b0705]).

Stress-induced changes in the amygdalar expression of NPY and Y1 receptors and a specific anti-stress action of intraamygdalar administration of NPY provide further evidence for an important role of NPY in stress processing. For instance, acute restraint stress decreases NPY expression in the amygdala, whereas intermittent restraint stress over a 10 day period or exposure to a variable stress paradigm for 1 week increases NPY expression within this structure ([@b0970; @b0960; @b0650]). In contrast, exposure to footshocks for as little as 15 min is able to enhance the amygdalar NPY expression as measured 2 weeks after the intervention ([@b0210]). Y1 receptor expression in the amygdala is increased by acute restraint stress, but left unaltered by prolonged restraint over a period of 10 days ([@b0670]), whereas a single session of inescapable foot shock reduces amygdalar Y1 receptor expression ([@b0415]). Transgenic NPY overexpression attenuates anxiety-like responses induced by restraint stress ([@b0965]) much as repeated infusion of NPY into the basolateral amygdala prevents stress-induced behavioural changes in the social interaction test ([@b0850]). Behavioural disturbances evoked by exposure of mice to predator-scent stress are followed by a marked downregulation of NPY in the hippocampus, periaqueductal grey and amygdala, and intracerebral administration of NPY after stress exposure can reduce the manifestation of stress-induced disruption of behaviour ([@b0180]).

Given that NPY promotes stress resilience and aids the recovery from stress, it is emerging that the NPY system also influences the impact of stress on the gut--brain axis. Exposure of rats to water avoidance stress lowers the plasma level of PYY, a change that is associated with an increase in gastrointestinal motility ([@b0580]). Trinitrobenzene sulfonic acid-induced colitis increases the NPY concentration in brain and plasma ([@b0065]) whereas the expression of NPY mRNA in the brain remains unaltered by *Helicobacter pylori* infection ([@b0110]). Gastrointestinal inflammation enhances anxiety- and depression-related behaviour in a gender-dependent manner ([@b0785; @b0760; @b0355]), these effects being modified by genetic deficiency of PYY and/or NPY. Specifically, the ability of experimental colitis to enhance anxiety-related behaviour in male mice is prevented by genetic deletion of PYY, but not NPY, whereas the increase in depression-like behaviour which DSS causes in female mice is abolished by NPY and PYY knockout ([@b0760]). These observations attest to distinct roles of PYY and NPY in the impact of intestinal inflammation on the gut--brain axis. In addition, the depression-like phenotype of PYY knockout animals ([@b0760]) suggests that alterations in the expression of this gut hormone modify mood and stress coping. The gender-related impact on behaviour may be related to a gender-dependent implication of NPY in the stress-evoked release of corticosterone ([@b0320]).

NPY is not only a stress mediator in the central nervous system but also in the periphery. The stress-related implications of NPY impact on many physiological systems including the cardiovascular system, the gastrointestinal tract, the immune system, metabolism, and adaptation to stress ([@b0430]). It is obvious that these implications also affect gut--brain and brain--gut communication. For instance, deletion of NPY alters gastrointestinal, feeding and corticosterone responses to restraint stress in a gender-dependent manner ([@b0320]). Thus, the stress-induced delay of upper gastrointestinal transit is more pronounced in female than in male NPY knockout mice. In addition, deletion of NPY exaggerates stress-induced defaecation and reduces food intake, these effects being gender-independent ([@b0320]). The stress-evoked release of corticosterone is enhanced by NPY deletion in male mice, and further experiments indicate that NPY inhibits corticosterone release via peripheral Y1 and Y2 receptor activation ([@b0320]).

3.7. PYY, PP and NPY regulate food intake and energy homeostasis {#s0065}
----------------------------------------------------------------

The gastrointestinal tract is a major endocrine organ that produces and releases a variety of messengers that act either in a paracrine or endocrine manner to coordinate digestion and regulate metabolic homeostasis. The implications of PP, PYY and NPY in gut--brain signalling are particularly well exemplified by their effects on hunger, food intake, satiety and energy balance. Since these roles have been extensively reviewed elsewhere ([@b0725; @b0315; @b0530; @b1070]), only some of the salient features are considered here. PP and PYY function as satiety factors, slowing the gastrointestinal transit of chyme, inhibiting further intake of food and modifying metabolic and energy homeostasis ([@b0315]). Since these actions take place, at least in part, in the brain, it should be concluded that PP and PYY are able to signal to the brain.

PP, which is a preferential agonist at Y4 receptors, is released postprandially from endocrine cells in pancreatic islets under vagal cholinergic control ([@b0880; @b0725; @b0315]). Peripheral administration of PP causes Y4 receptor-dependent neuronal stimulation (c-Fos expression) in the brainstem, hypothalamus and amygdala ([@b0950]). However, it is not clear whether PP can directly reach these cerebral structures, although there is evidence that PP can enter the brain ([@b0480; @b0055]) preferentially via circumventricular organs such as the area postrema ([@b0240]). PP causes a negative energy balance by decreasing food intake and gastric emptying and by increasing energy expenditure, these effects also involving the vagus nerve ([@b0040; @b0725; @b0315]). Knockout of the Y4 gene leads to an increase in nocturnal feeding ([@b0265]), while transgenic overexpression of PP in mice reduces food intake and body weight gain ([@b0995]). A reduction of food intake by PP is also seen in lean humans as well as in obese patients with Prader-Willi syndrome ([@b0115; @b0085]). In the rodent brain, Y4 receptors have been localised to the medulla, locus coeruleus, hypothalamus, hippocampus, medial and basolateral amygdala, and ventral tegmental area ([@b0235; @b0795; @b0135; @b0310]). While the role of Y4 receptors in synaptic transmission is little known, Y4 receptors in the hypothalamus are involved in presynaptic inhibition of transmitter release ([@b0005]).

PYY is released postprandially from intestinal L cells in proportion to energy intake ([@b0315]) and in part truncated to PYY~3--36~ which is the main circulating form of PYY and a relatively selective Y2 receptor agonist. PYY and PYY~3--36~ inhibit gastric acid secretion, gastrointestinal transit and food intake in rodents and humans ([@b0075; @b0150; @b0745; @b0545; @b0315]). The anorectic effect of PYY~3--36~ is seen in both lean and obese subjects and in higher doses is associated with nausea and vomiting ([@b0075; @b0070; @b0315]). Food intake is inhibited by PYY~3--36~ both via a stimulant effect on Y2 receptors on vagal afferent neurons ([@b0545; @b1000]) and an interaction with Y2 receptors in the hypothalamus. This is consistent with the ability of PYY~3--36~ to gain access to the brain via circumventricular organs such as the area postrema and subfornical organ ([@b0240]) but also to permeate the blood--brain barrier to a certain extent ([@b0745]).

Within the brain, PYY~3--36~ reduces food intake primarily via activation of Y2 receptors in the arcuate nucleus which is an important centre for integrating peripheral and central signals in the control of appetite and energy homeostasis ([@b0160]). The arcuate nucleus contains at least two populations of neurons that are relevant in this respect: orexigenic neurons expressing NPY and AgRP and anorexigenic neurons expressing pro-opiomelanocortin (POMC). These neurons send projections to various areas of the hypothalamus (including the paraventricular nucleus) and reciprocally inhibit the orexigenic/anorexigenic tone exerted by NPY/AgRP neurons and POMC neurons, respectively ([@b0160]). The anorectic effect of PYY~3--36~ is mediated primarily by presynaptic Y2 receptors on NPY/AgRP neurons in the arcuate nucleus, inhibiting their orexigenic action and disinhibiting POMC neurons ([@b0075; @b0725; @b1000; @b0315]). In addition, peripheral infusion of PYY~3--36~, at doses mimicking the plasma levels of PYY~3--36~ in the fed state, modulates neural activity in corticolimbic areas ([@b0080]).

NPY is one of the most potent orexigenic peptides found in the brain ([@b0160; @b1070]), the NPY/AgRP neurons in the arcuate nucleus taking a central place in this respect. Their orexigenic effect is primarily mediated by Y1 receptors, although Y5 receptors also play a role ([@b1070]). Selective ablation of NPY/AgRP neurons in the arcuate nucleus of adult mice results in a life-threatening reduction of food intake ([@b0370; @b0600]). These finding indicates that feeding depends critically on the function of NPY/AgRP neurons. Conversely, pathologies associated with a decrease in food intake such as experimental colitis lead to increased release of NPY from the paraventricular nucleus of the hypothalamus ([@b0050]). Experiments with NPY knockout mice attest to a physiological function of endogenous NPY in balancing energy intake with physical activity-related energy expenditure ([@b0260; @b1070]). Besides the hypothalamus, many other neuronal systems in the brain express NPY, and it is likely that some of these NPY neurons (e.g., in the brainstem, nucleus accumbens and corticolimbic system) likewise play a role in the regulation of appetite and food intake.

3.8. PYY, PP and other gut hormones regulate anxiety and mood {#s0070}
-------------------------------------------------------------

Apart from regulating ingestion and energy homeostasis, gut hormones such as ghrelin, PYY, glucagon-like peptide-1 and glucagon-like peptide-2 have also an impact on emotional-affective behaviour. Seen from an evolutionary point of view, co-regulation of appetite and emotional state is an important strategy for survival, given that anxiety would be an adverse condition when there is a need to seek food. Indeed, ghrelin which is released from the upper gastrointestinal tract under conditions of hunger reduces both anxiety-like and depression-related behaviour ([@b0605]). Under fed conditions, behaviour is changed to a hedonic state as observed when PYY~3--36~ is administered to reach postprandial plasma concentrations of the peptide ([@b0080]). Physiologically, however, emotion and mood under fed conditions will be determined by the presence of a variety of gut hormones that are released postprandially. Among these, glucagon-like peptide-1 has been found to enhance anxiety-related behaviour ([@b0700; @b0525; @b0380]), while glucagon-like peptide-2 attenuates depression-like behaviour ([@b0485]).

The ability of PYY to promote hedonic behaviour is supported by the finding that knockout of PYY increases depression-like behaviour but does not alter anxiety ([@b0760]). This finding indicates that the gut hormone PYY or its major circulating form, PYY~3--36~, is able to signal to the central nervous system, either by gaining direct access to the brain ([@b0745; @b0240]) or by activating vagal afferent input to the brainstem ([@b0545; @b1000]). Although the biological actions of PYY~3--36~ are mediated primarily by Y2 receptors, it is not yet understood which Y receptors mediate the antidepressant effect of gut-derived PYY, given that stimulation of Y2 receptors in the brain increases anxiety- and depression-like behaviour ([@b0405]). In addition, knockout of Y2 receptors reduces anxiety-related and depression-like behaviour and impairs learning and memory ([@b0985; @b0825; @b0830; @b0780; @b0950; @b0955]). The anxiolytic and antidepressant action of Y2 receptor knockout has been localised to the deletion of presynaptic Y2 receptors in the central and basolateral amygdala ([@b0955]).

PP whose biological actions are preferentially mediated by Y4 receptors is also able to influence emotional-affective behaviour. Thus, anxiety- and depression-like behaviour is attenuated and novelty-evoked locomotion increased in Y4 receptor knockout mice ([@b0780; @b0950]). The anxiolytic-like phenotype of Y4 receptor knockout mice is consistent with the anxiogenic phenotype of PP-overexpressing mice ([@b0990]). Since intracerebroventricular PP fails to alter anxiety-related behaviour ([@b0035]) while chronic peripheral administration of PP reduces anxiety ([@b0040]), it would appear that PP modifies anxiety- and depression-like behaviour through an action in the periphery or in the area postrema outside the blood--brain barrier ([@b0565; @b0240; @b0950]). This possibility is backed by the ability of peripheral PP to induce Y4 receptor-dependent c-Fos expression in brainstem, hypothalamus and amygdala and by the expression of an appreciable number of Y4 receptors in these regions ([@b0950]). In addition, knockout of the Y4 receptor is associated with an increase in the circulating level of PP ([@b0845]).

4. Conclusions {#s0075}
==============

As outlined in this review, the study of the gut--brain axis has proved to be of major relevance not only to gastroenterology but also to experimental and clinical neuroscience, notably psychiatry. The gut microbiota which is a symbiotic superorganism by itself, the intestinal mucosa and the intestinal immune system issue multiple signals to the brain. These signals are carried by sensory neurons, immune mediators, gut hormones and microbiota-derived signalling molecules. In disease, this input from the gastrointestinal tract gives rise to disturbances of digestion and gastrointestinal function, pain and hyperalgesia, emotional-affective disturbances, defective stress coping and cognitive impairment. In addition, the autonomic and neuroendocrine outputs of the brain to the gut may also be deranged.

The NPY-Y receptor system provides several targets whereby gut--brain axis disorders could potentially be managed. The different members of this peptide family, NPY, PYY and PP, operate both as neural and endocrine messengers at distinct levels of the gut--brain axis ([Fig. 2](#f0010){ref-type="fig"}). PYY and PP are exclusively expressed by endocrine cells of the digestive system, whereas NPY is found at all levels of the gut--brain and brain--gut axis. In the gastrointestinal tract, NPY and PYY inhibit gastrointestinal motility and electrolyte secretion and may also interact with the intestinal microbiota. Y1 receptors operated by NPY exert a proinflammatory action in the gut, and the NPY-Y receptor system protects against distinct behavioural disturbances caused by peripheral immune challenge, attenuating the acute sickness response and preventing the development of long-term depression. Similarly, NPY inhibits nociceptive input from the periphery to the spinal cord and brainstem. In the brain, NPY and its receptors (Y1, Y2, Y4, Y5) play important roles in regulating locomotion, exploration, food intake, energy homeostasis, anxiety, mood and stress resilience. This action profile is in part shared by the gut hormones PP and PYY which signal to the brain to attenuate food intake, anxiety and depression-related behaviour.

These findings underscore an important role of the NPY-Y receptor system at several levels of the gut--brain axis and support the hypothesis that Y receptors are worthwhile targets for the therapy of gut--brain axis disorders such as IBS. Unfortunately, the pharmacology of the NPY-Y receptor system is developed only to a limited extent so that many therapeutic opportunities arising from the implications of the NPY-Y receptor system in the gut--brain axis cannot yet be thoroughly evaluated. However, gene knockout and transgenic approaches attest to the validity of the NPY system as a therapeutic target, a conclusion that is increasingly supported by clinical studies. Given that the NPY-Y receptor system operates as a multi-level homeostatic mechanism, pharmacological manipulation of this system may have considerable therapeutic efficacy.
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![The bidirectional gut--brain axis. Four communication pathways (sensory neurons, cytokines, gut hormones and microbial factors) signal from the gut to the brain where they can modify cerebral function and behaviour. Two pathways (autonomic and neuroendocrine outputs) signal from the brain to the gut. EC, M and L denote different populations of endocrine cells in the gastrointestinal mucosa.](gr1){#f0005}

![The NPY-Y receptor sytem in the gut--brain axis. The graph shows the major sources of NPY, PYY and PP along the gut--brain axis and the Y receptor subtypes which mediate the effects of these peptides at the different levels of the gut--brain axis. The arrow symbols denote stimulation, the tack symbols denote inhibition.](gr2){#f0010}
